0001573202-17-000012.txt : 20171212 0001573202-17-000012.hdr.sgml : 20171212 20171212193821 ACCESSION NUMBER: 0001573202-17-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171209 FILED AS OF DATE: 20171212 DATE AS OF CHANGE: 20171212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SAPIRSTEIN JAMES CENTRAL INDEX KEY: 0001559509 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16467 FILM NUMBER: 171252829 MAIL ADDRESS: STREET 1: 1517 SAN JACINTO CITY: HOUSTON STATE: TX ZIP: 77002 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RespireRx Pharmaceuticals Inc. CENTRAL INDEX KEY: 0000849636 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330303583 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 126 VALLEY ROAD STREET 2: SUITE C CITY: GLEN ROCK STATE: NJ ZIP: 07452 BUSINESS PHONE: (201) 444-4947 MAIL ADDRESS: STREET 1: 126 VALLEY ROAD STREET 2: SUITE C CITY: GLEN ROCK STATE: NJ ZIP: 07452 FORMER COMPANY: FORMER CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/ DATE OF NAME CHANGE: 19920703 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2017-12-09 0 0000849636 RespireRx Pharmaceuticals Inc. RSPI 0001559509 SAPIRSTEIN JAMES C/O RESPIRERX PHARMACEUTICALS INC. 126 VALLEY ROAD, SUITE C GLEN ROCK NJ 07452 1 0 0 0 Common Stock Options (to purchase shares of Common Stock) 1.45 2017-12-09 4 J 0 38114 A 2022-12-09 Common Stock 38114 38114 D Common Stock Options (to purchase shares of Common Stock) 2 2022-06-30 Common Stock 25000 25000 D Common Stock Options (to purchase shares of Common Stock) 3.9 2022-01-18 Common Stock 25000 25000 D Common Stock Options (to purchase shares of Common Stock) 7.3775 2021-03-31 Common Stock 30770 30770 D Common Stock Options (to purchase shares of Common Stock) 6.396 2022-08-18 Common Stock 9231 9231 D Common Stock Options (to purchase shares of Common Stock) 8.125 2022-06-30 Common Stock 6154 6154 D On December 9, 2017, Mr. Sapirstein forgave all of the accrued but unpaid directors fees to which he was entitled as of September 30, 2017, an aggregate of $55,000. On that date, the Company granted to Mr. Sapirstein options to purchase 38,114 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $55,000. These Common Stock Options vested upon issuance. These Common Stock Options vested upon issuance. These Common Stock Options vested in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017, and are all currently vested. The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016, and are all currently vested. These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested. These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016, and are all currently vested. The Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested. /s/ James E. Sapirstein 2017-12-11